{"url_path":"/sec/imnm/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1472012/0001193125-26-344577-index.html","accession_number":"0001193125-26-344577","cik":"0001472012","ticker":"IMNM","issuer_name":"Immunome Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1472012/0001193125-26-344577-index.html","primary_entity_key":"0001472012","primary_entity_name":"Immunome Inc."},"word_count":158,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, Immunome, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2026 and provided a business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.\n\nThe information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing."}